The TBPod Actnet

Today we speak with Dr Guglielmetti about the END-TB trial which looks at new all oral regimens for MDR-TB.

REFERENCES
1) https://endtb.org/
2) Nyang’wa, Bern-Thomas, et al. "A 24-week, all-oral regimen for rifampin-resistant tuberculosis." New England Journal of Medicine 387.25 (2022): 2331-2343.
3) Conradie, Francesca, et al. "Treatment of highly drug-resistant pulmonary tuberculosis." New England Journal of Medicine 382.10 (2020): 893-902.
4) Diacon, Andreas H., et al. "Multidrug-resistant tuberculosis and culture conversion with bedaquiline." New England Journal of Medicine 371.8 (2014): 723-732.
5) Gler, Maria Tarcela, et al. "Delamanid for multidrug-resistant pulmonary tuberculosis." New England Journal of Medicine 366.23 (2012): 2151-2160.
6) Ahmad, Nafees, et al. "Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis." The Lancet 392.10150 (2018): 821-834.
7) Lan, Zhiyi, et al. "Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis." The Lancet Respiratory Medicine 8.4 (2020): 383-394.
APA | 

Today we delve into the world of TB diagnostics and the future of leveraged TB technologies with Dr Morten Ruhwald. Dr Ruhwald is a the head of the TB programme over at FIND, an institution dedicated to accelerating equitable access to reliable diagnosis around the world. Dr Ruhwald elaborates on the current state of TB diagnostics, new clinical strategies, usability factors,  and future TB perspectives.

https://www.finddx.org/what-we-do/programmes/tuberculosis/

https://www.actnet.org.au/

Today we speak with Dr Chris Lowbridge about the amazing work of the TB teams in the Northern Territory. Chris talks about the challenges of controlling tuberculosis across 1.42 million square kilometres, more than 100 local languages, and some very isolated communities.

References
Meumann, Ella M., et al. "Tuberculosis in Australia's tropical north: a population-based genomic epidemiological study." The Lancet Regional Health–Western Pacific 15 (2021).

Vigneswaran, Nilanthy, et al. "Factors leading to diagnostic delay in tuberculosis in the tropical north of Australia." Internal Medicine Journal (2023).

Coorey, N. J., et al. "Risk factors for TB in Australia and their association with delayed treatment completion." The International Journal of Tuberculosis and Lung Disease 26.5 (2022): 399-405.

Francis, J. R., et al. "Multidrug-resistant tuberculosis in Australia, 1998–2012." The international journal of tuberculosis and lung disease 22.3 (2018): 294-299.

Today we speak with Dr Clifton Barry from NIH in Bethesda, Maryland who is head of the most highly cited research group in the field of TB over the past year and has made extraordinary contributions to TB drug development. Dr Barry speaks about his involvement in the PREDICT TB study, the TB Drug Accelerator and some of the most exciting drug developments in recent years.

REFERENCES
Green, Simon R., et al. "Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs." Nature communications 13.1 (2022): 5992.

https://predict-tb.com/

Lange, Christoph, Clifton E. Barry III, and C. Robert Horsburgh Jr. "Treatments of multidrug-resistant tuberculosis: light at the end of the tunnel." American Journal of Respiratory and Critical Care Medicine 205.10 (2022): 1142-1144.

Khan, RM Naseer, et al. "Distributable, metabolic PET reporting of tuberculosis." bioRxiv (2023).

Cole, STea, et al. "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence." Nature 396.6707 (1998): 190-190.

Finin, Peter, et al. "Chemical approaches to unraveling the biology of mycobacteria." Cell Chemical Biology 30.5 (2023): 420-435.

Libardo, M. Daben J., et al. "Resistance of Mycobacterium tuberculosis to indole 4-carboxamides occurs through alterations in drug metabolism and tryptophan biosynthesis." Cell Chemical Biology 28.8 (2021): 1180-1191.

Barry, Clifton E., Helena IM Boshoff, and Cynthia S. Dowd. "Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis." Current pharmaceutical design 10.26 (2004): 3239-3262.

Xie, Yingda L., et al. "Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis." Science Translational Medicine 13.579 (2021): eabd7618.

Today we get an update on where the TB Vaccine pipeline is up to, how TB vaccines work and what exciting candidates might be on the horizon. We speak with Professor Jamie Triccas from the University of Sydney about his work as the principal investigator on the Advancing Vaccine Adjuvant Research for Tuberculosis (AVAR-T) which is an NIH funded project to identify the most promising adjuvant-TB immunogenicity candidates for development.

REFERENCES
Stewart, Erica, James A. Triccas, and Nikolai Petrovsky. "Adjuvant strategies for more effective tuberculosis vaccine immunity." Microorganisms 7.8 (2019): 255.

Counoupas, Claudio, James A. Triccas, and Warwick J. Britton. "Deciphering protective immunity against tuberculosis: implications for vaccine development." Expert Review of Vaccines 18.4 (2019): 353-364.

Triccas, James A., and Jonathan K. Nambiar. "Challenge of developing new tuberculosis vaccines to generate life-long protective immunity." Expert Review of Vaccines 8.7 (2009): 823-825.

Counoupas, Claudio, et al. "Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis." npj Vaccines 5.1 (2020): 105.

Counoupas, Claudio, and James A. Triccas. "The generation of T‐cell memory to protect against tuberculosis." Immunology and Cell Biology 97.7 (2019): 656-663.

Triccas, James A., and Claudio Counoupas. "Novel vaccination approaches to prevent tuberculosis in children." Pneumonia 8 (2016): 1-7.

Counoupas, Claudio, et al. "Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis." Vaccine 36.19 (2018): 2619-2629.

Counoupas, Claudio, et al. "Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice." npj Vaccines 1.1 (2016): 1-11.

Today we have the pleasure of speaking with Professor Giovanni Migliori about TB Elimination. Professor Migliori is the director of the WHO collaborating centre for TB and lung disease and is the current chief editor for the international journal of TB and lung disease. He was formerly the secretary general of the ERS and president of the Union's European region. Today he speaks about his recent viewpoint publication regarding how different countries should be approaching TB control and elimination and why it's important for different countries to target different objectives.

References:
Migliori, Giovanni Battista, et al. "The path to tuberculosis elimination: a renewed vision." European Respiratory Journal 61.6 (2023).

Chiara, Ippoliti. "WHO targets elimination of TB in over 30 countries." Central European Journal of Public Health 22.3 (2014): 158-163.

Lönnroth, Knut, et al. "Towards tuberculosis elimination: an action framework for low-incidence countries." European Respiratory Journal 45.4 (2015): 928-952.

D'Ambrosio, Lia, et al. "Tuberculosis elimination: theory and practice in Europe." European Respiratory Journal 43.5 (2014): 1410-1420.

Matteelli, Alberto, et al. "Tuberculosis elimination: where are we now?." European Respiratory Review 27.148 (2018).

Diel, Roland, et al. "Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination." European Respiratory Journal 42.3 (2013): 785-801.

Matteelli, Alberto, et al. "Tuberculosis elimination and the challenge of latent tuberculosis." La Presse Médicale 46.2 (2017): e13-e21.

Voniatis, Constantia, et al. "Tuberculosis elimination: dream or reality? The case of Cyprus." European Respiratory Journal 44.2 (2014): 543-546.

Rendon, Adrian, et al. "Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance." European Respiratory Journal 48.5 (2016): 1282-1287.

Al Yaquobi, Fatma, et al. "Tuberculosis elimination: a dream or a reality? The case of Oman." European Respiratory Journal 51.1 (2018).